Pharmacotherapy of poststroke sensorimotor deficits is currently used alone or combined with physiotherapy to promote recovery of mobility problems. This case study examined the effectiveness of donepezil hydrochloride (HCl) administered to a stroke patient with chronic, dense, left sensorimotor deficit. The patient received donepezil HCl (5 mg daily for 4 wk, followed by 10 mg daily for 12 wk) but no physiotherapy. Baseline and posttreatment evaluations were performed with the Fugl-Meyer scale and the Rivermead Mobility Index. One month after starting donepezil HCl (10 mg/day), sensorimotor function improved dramatically in the hemiplegic lower limb and shoulder. It was concluded that donepezil HCl may be an effective treatment for improving sensorimotor function in chronic stroke patients. Randomized controlled trials are required to support these preliminary findings.
produces prolonged functional improvement, 3 and psychostimulant treatments in combination with physiotherapy improve functional motor recovery. 4, 5 Pharmacologic treatments in stroke patients are directed to restore neurotransmitter system deficiencies, and agents that restore or augment norepinephrine, dopamine, and serotonin activity have been used to promote recovery of hemiplegia, neglect, and aphasia. 4 -6 Recent studies in animal models and in humans indicate that central cholinergic neurotransmission is involved in motor function. [7] [8] [9] A positron emission tomography study in monkeys found that activation of the somatosensory cortex induced by contralateral somatosensory stimulation is abolished by scopolamine and reversed by physostigmine and tacrine. 7 Transcranial magnetic stimulation (TMS) studies in healthy volunteers found that antagonists of muscarinic receptors (atropine, scopolamine) modify the excitability of the motor cortex 8 and substantially attenuate the magnitude of use-dependent plasticity. 9 Donepezil hydrochloride (HCl) is a reversible acetylcholinesterase inhibitor with a selective central action. 10 It is safe and widely prescribed to improve cognition and memory in patients with Alzheimer's disease and other neurologic conditions (i.e., head trauma). 10, 11 To evaluate the efficacy of cholinergic therapy in improving sensorimotor deficits associated with stroke, we used donepezil HCl to treat a stroke patient and examined its effects on cortical reorganization using functional magnetic resonance imaging (fMRI) and neurophysiologic techniques.
CASE REPORTS
The patient was a 64-yr-old, strongly right-handed woman who, at age 59, suffered a large right-hemisphere ischemic infarction, which left her with a dense left hemiplegia, left hemisensory loss, and "crossed" conduction aphasia. After the stroke, she received two sessions of traditional physiotherapy daily for 2 yr. Because she was unable to recover voluntary movements, physiotherapy was stopped, and she had not received physiotherapy since then. By that time, an MRI disclosed a large infarct in the vascular territory of the right middle cerebral artery involving the temporoparietal cortex and extending deeply into the posterior insula, putamen, corona radiata, and internal capsule. There was a severe shrinkage of the right cerebral peduncle. The inferior frontal, primary sensorimotor, dorsolateral prefrontal, and mesial frontoparietal cortices and the thalamus and a small portion of the posterior limb of the internal capsule were spared. After signing an informed consent agreement, the patient received 5 mg of donepezil HCl daily for 1 mo, followed by 10 mg daily for 3 mo, and thereafter, a 4-wk washout period. Adverse events were monitored during therapy. Two weeks after receiving donepezil HCl (5 mg/day), the patient developed touch-and warmth-evoked allodynia in the left foot, calf, and forearm. Allodynia lasted 2 wk, and its disappearance coincided with the recovery of sensation for touch, temperature, and joint-position sense in the left leg and arm. Four weeks after starting 10 mg of donepezil HCl, she began to recover voluntary movements of the left leg and shoulder, but the left hand remained totally plegic. Eight weeks later, her Fugl-Meyer scale score increased to 34 (motor component for upper limb, 7; motor component for lower limb, 18' sensation, 9) and her Rivermead Mobility Index score to 13. Recovery of motor function in the left foot was associated with the development of mirror movements, yet passive flexion-extension exercises of the left foot did not elicit visible movements in the unaffected right foot. Donepezil HCl did not induce adverse effects. Withdrawal evaluation 4 wk later revealed the maintenance of gains in sensorimotor function obtained during treatment (Fugl-Meyer scale score, 34; Rivermead Mobility Index score, 13).
ANCILLARY STUDIES
Twelve weeks after starting donepezil HCl treatment (10 mg/day), the functional correlates of recovery were examined with fMRI and neurophysiologic techniques (Bereitschaftspotential and TMS).
Functional MRI. The patient was scanned 12 wk after initiation of donepezil HCl treatment (10 mg/day) on a 1.5-T magnetic resonance scanner (Signa, GE Medical Systems, Milwaukee, WI) equipped with echospeed gradients and single-shot echoplanar imaging software. 15, 16 Eight interleaved slices, parallel to the anteroposterior commissure line, were obtained for each functional sequence to cover the cortical motor system (four slices). 16, 17 The functional time series consisted of 60 con-secutive images obtained in 3 min, in which 30-sec periods of rest and activation were alternated. The patient was instructed to perform active, selfinitiated movements of the left foot. In addition, passive flexion-extension movements were performed by the examiner to assess the proprioceptive sensory input of the motor-sensory loop. 6 Foot exercises were selected because recovery of motor function during donepezil HCl treatment mainly took place in the distal left leg and because active shoulder movements of the plegic arm induced head movements.
Bereitschaftspotential. The Bereitschaftspotential (BP) recordings were obtained with an analogic amplifier (Grass 8-pluss electroencephalogram) and further processed using an analog/digital converter Neuroscan 3.0 (Herdnon, VA). Brisk voluntary unilateral extensions of the left deltoid muscle (recorded by surface electromyography) were repeated at a self-paced rate of every 4 -5 sec. The electroencephalographic segments from 2 sec before to 1 sec after the trigger movement were digitized and stored at a sampling rate of 400 Hz. The stored electroencephalographic segments were average-time locked to the precise onset of the rectified electromyograph, which was determined through off-line inspection of each trial. During this procedure, trials with apparently significant artifacts were excluded. The amplitude of the early BP component (650 msec before electromyographic onset) and the late BP component (negative slope, maximal BP negativity peak minus BP negativity peak at 650 msec before electromyographic onset) were identified by visual inspection.
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TMS. TMS was delivered using a 90-mm outer diameter circular coil, which was applied centered at the vertex with a posterior-to-anteriorinduced current for the stimulated hemisphere (Magstim Rapid, Carmarthenshire, UK 
RESULTS
Functional MRI. Active flexion-extension movements of the paretic left foot basically induced activation of the contralateral right mesial sensorimotor cortex, together with functional activity in the supplementary motor area (Fig. 1) . The activation pattern was accurately replicated in a second fMRI trial with the active task, and similar results were obtained after passive flexion-extension movements of the left foot (Fig. 1) .
Bereitschaftspotential. The voluntary contraction of the left deltoid muscle was preceded by a BP of higher amplitude in the ipsilateral electroencephalographic leads, especially in the late part or negative slope. Ipsilateral leads, early/late parts: F3, 7.7/11.8 V; C3, (Fig. 2) .
TMS.
Motor threshold for the right abductor pollicis brevis muscle and central conduction time elicited with TMS were within normal limits (62% and 9.0 msec, respectively). The MEP latency at the right abductor pollicis brevis muscle was 22.8 msec and 11.8 msec at the right deltoid muscle. Interestingly, a MEP was also recorded at the ipsilateral deltoid muscle with a latency of 24.1 msec (Fig. 2) . When stimulation was applied over the right motor cortex, no MEPs were recorded at the abductor pollicis brevis or at the deltoid muscles, even at the maximal stimulator output intensity.
DISCUSSION
In the present case, recovery of chronic sensorimotor deficits followed donepezil HCl treatment, administered 5 yr after onset. Such a late response in a stroke patient in the absence of a concomitant physiotherapy treatment that can by itself explain the patient's recovery, coupled with allodynia preceding sensory recovery and the improvement of left foot and shoulder movements, suggest that donepezil HCl enhanced neural activity in surviving brain systems. To the best of our knowledge, this is the first study that examines the efficacy of donepezil HCL on poststroke sensorimotor deficits. The cortical activation pattern correlating with recovered foot functions was documented with fMRI as an almost identical pattern of activation of the contralateral mesial somatosensory cortex and the supplementary motor area during active and passive left foot movements. Neurophysiologic techniques (BP and TMS) showed an enhancement of ipsilateral motor representations during active movements of the left shoulder, suggesting recruitment of ipsilateral motor pathways. 19 Structural MRI disclosed a large right cortical infarct with subcortical extension and major involvement of the corticospinal motor and sensory pathways, except for a small part of the posterior limb of the internal capsulae and the "leg representation zone" in mesial somatosensory cortex (Brodmann's areas 4, 312, and 5). Moreover, these structurally intact peri-infarct regions still showed a marked hypoperfusion on a brain single photon emission computed tomography performed 2 yr after stroke onset. Thus, it is possible that these islets of spared parenchyma did not promote functional recovery of the hemiplegic lower limb under physical therapy because they remained disconnected for a long period after the stroke as a result of enduring central input alterations. 20 The earliest clinical changes during donepezil HCl (5 mg/day) treatment involved improvement of deficits in left foot sensation, perhaps through a short-lived maladaptive reorganization resulting in touch-and warmth-evoked allodynia, followed by left leg motor recovery and proximal left arm improvement. Recent evidence in humans shows that reduced input to a cortical sensory region leads to reduced excitability of adjacent motor cortex 20 and that somatosensory stimulation increases hand muscle strength of stroke patients. 21 It is therefore possible that donepezil HCl contributes in reversing the deprivation of sensory input by activating sensory processing and ultimately promoting motor function recovery. Maladaptive plastic changes also occurred for motor function because functional recovery in the left foot was associated with the development of mirror movements.
Reorganization of the motor system was probably not confined to the contralateral somatosensory cortex. Less dramatic, though clinically evident, left shoulder recovery was also observed. Because of the virtually massive damage to the internal capsule, the recovered motor function in this bodily region was presumably controlled by ipsilateral structures, as suggested by BP and TMS, that may also be receptive to the beneficial action of donepezil HCl. Although our findings suggest that donepezil HCl is a potentially viable treatment option for patients with chronic poststroke sensorimotor deficits, randomized, controlled clinical trials are necessary to support these preliminary findings.
